Exact Sciences (Abbott)
Exact Sciences makes Cologuard and Oncotype DX and is launching Cancerguard MCED and Oncodetect MRD; it is being acquired by Abbott for $21B.
Cologuard Plus, Oncotype DX, Oncodetect (MRD), Cancerguard (MCED, LDT 2025).
Pages like this
not linked directly; found by shared links- IdeaA cancer blood test for older people arriving at A&E with unexplained symptoms
Shares Multi-cancer early detection (MCED), Most lethal cancers are found late.
- IdeaCheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress
Shares MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- ProductShield
Shares Early detection roadmap: organ screening → blood tests for many cancers, Multi-cancer early detection (MCED), Most lethal cancers are found late, Colorectal cancer.
- CompanyFreenome
Shares Multi-cancer early detection (MCED), Most lethal cancers are found late, Colorectal cancer.
- IdeaUse a polygenic risk score to set when screening starts
Shares Most lethal cancers are found late, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- CompanyHarbinger Health
Shares Multi-cancer early detection (MCED), Most lethal cancers are found late.
- IdeaBank yearly blood from cancer survivors so future tests can be validated
Shares Multi-cancer early detection (MCED), Most lethal cancers are found late, MRD / molecular residual disease testing.
- TrialPATHFINDER 2
Shares Early detection roadmap: organ screening → blood tests for many cancers, Multi-cancer early detection (MCED), Most lethal cancers are found late.